Nova Patents
EP0206532A3

Fibrinogen blocking monoclonal antibody

Abstract

There is provided a novel monoclonal antibody of the class laG1 which reacts readily with both normal human and dog blood platelets while failing to react with thrombasthenic human platelets. This antibody has the property of completely blocking interaction of fibrinogen with platelets induced by ADP.

Term

Term ended

Projected expiry passed 23 May 2006, 20.3 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

18 members in 7 offices

This recordMember, by publication datePriority claim

Priority claims4

Priority claims
DocumentOfficeKindDate
742208United States of America–
74220885United States of AmericaA
742208–––
US19850742208–––

Members18

Family members, oldest first
DocumentOfficeKind
EP0206532A2European Patent Office (EPO)A2
EP0206533A2European Patent Office (EPO)A2
JPS6229995AJapanA
JPS6230728AJapanA
EP0206532A3This recordEuropean Patent Office (EPO)A3
EP0206533A3European Patent Office (EPO)A3
CA1297815CCanadaC
CA1297816CCanadaC
US5275812AUnited States of AmericaA
EP0206533B1European Patent Office (EPO)B1
AT104316TAustriaT
DE3689779D1GermanyD1
US5336618AUnited States of AmericaA
DE3689779T2GermanyT2
US5387413AUnited States of AmericaA
US5440020AUnited States of AmericaA
JP2524978B2JapanB2
HK1007746A1Hong Kong, ChinaA1